Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

Actor struggles to pay litigation fees What changes did IU make to her makeup while playing Oh Ae Sun on When Life Gives You Tangerines? Fans have ideas The internet went abuzz with gossip after a ...

Ozempic, initially for type 2 diabetes, has gained popularity for rapid weight loss, leading to a newly reported side effect ...

Orforglipron, an oral GLP-1 receptor agonist developed by Eli Lilly, has shown positive Phase 3 results in treating type 2 ...

As GLP-1 weight loss drugs have surged in popularity, the Food and Drug Administration has ordered medical professionals offering compounded versions of these drugs to stop services on April 22.

Injectable medications originally developed for the treatment of diabetes are also effective for weight loss and have surged ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...

The former Playboy model, 39, started injecting the drug after being body-shamed by internet trolls earlier this year.

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

“There is some evidence that there is altered brain activity related to reward-related behaviors, including appetite and ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...